Larry H. Matherly
Affiliations: | Wayne State University, Detroit, MI, United States |
Area:
Pharmacology, Biochemistry, Molecular BiologyWebsite:
https://cancerbiologyprogram.med.wayne.edu/faculty/matherlyGoogle:
"Larry Howard Matherly" OR "Larry H. Matherly"Bio:
https://books.google.com/books?id=ybIvAQAAIAAJ
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Allen Thurman Phillips | grad student | 1981 | Penn State | |
| (The catalytic mechanism of urocanase) | ||||
Children
Sign in to add trainee| Bee C. Ding | grad student | 2002 | Wayne State |
| Johnathan R. Whetstine | grad student | 2002 | Wayne State |
| Scott Payton | grad student | 2006 | Wayne State |
| Amanda Larson Gedman | grad student | 2010 | Wayne State |
| Sita K. Desmoulin | grad student | 2012 | Wayne State |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kaku K, Ravindra MP, Tong N, et al. (2023) Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport. Acs Medicinal Chemistry Letters. 14: 1682-1691 |
| Tong N, Wong-Roushar J, Wallace-Povirk A, et al. (2023) Multitargeted 6-Substituted Thieno[2,3-]pyrimidines as Folate Receptor-Selective Anticancer Agents that Inhibit Cytosolic and Mitochondrial One-Carbon Metabolism. Acs Pharmacology & Translational Science. 6: 748-770 |
| Hou Z, Gangjee A, Matherly LH. (2022) The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22164 |
| Wallace-Povirk A, Tong N, Wong-Roushar J, et al. (2021) Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors. Bioorganic & Medicinal Chemistry. 37: 116093 |
| O'Connor C, Wallace-Povirk A, Ning C, et al. (2021) Folate transporter dynamics and therapy with classic and tumor-targeted antifolates. Scientific Reports. 11: 6389 |
| Golani LK, Islam F, O'Connor C, et al. (2020) Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier. Bioorganic & Medicinal Chemistry. 28: 115544 |
| Li Petri G, El Hassouni B, Sciarrillo R, et al. (2020) Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer |
| Sarkisjan D, Julsing JR, El Hassouni B, et al. (2020) RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier. International Journal of Molecular Sciences. 21 |
| Dekhne AS, Ning C, Nayeen MJ, et al. (2019) Cellular pharmacodynamics of a novel pyrrolo[3,2-d]pyrimidine inhibitor targeting mitochondrial and cytosolic one-carbon metabolism. Molecular Pharmacology |
| Xiang W, Dekhne A, Doshi A, et al. (2019) Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis. Bioorganic & Medicinal Chemistry. 115125 |